Ionis Pharma’s Drug for Rare Disease With No Approved Therapies Meets Goals of Pivotal Study

Ionis Pharmaceuticals plans a 2026 FDA submission for zilganersen as a treatment for Alexander disease, an ultra-rare inherited neurological disorder. The antisense oligonucleotide developer has been moving toward commercializing drugs on its own rather than seeking partners. The post Ionis Pharma’s Drug for Rare Disease With No Approved Therapies Meets Goals of Pivotal Study appeared…

Read More

Extending Care Beyond the Hospital Walls

Fighting cancer is hard enough. Everyone deserves to heal in a clean, peaceful space. How one Crothall team is bringing comfort and control to patients in treatment When you’re in the middle of treatment for gynecologic cancer, even simple things like cleaning your home or apartment can feel impossible. “Because I was mentally foggy from…

Read More